The purpose of the study is to evaluate the absorption, distribution, metabolism and excretion of AZD1656 after administration of a single oral dose of 14C-labelled AZD1656 solution in male Type 2 Diabetes Mellitus patients.

Inclusion Criteria:

• Male type II diabetes patients diagnosed for more than 5 years and aged between 35 and 65 years.
• Subjects treated with metformin alone or metformin and one other oral anti-diabetic drug.
• Subjects should have FPG in the range of 6.0 to 11.0 mmol/L at screening and HbA1c less than 10% (HbA1c value according to international DCCT standard).

Exclusion Criteria:

• History of ischemic heart disease, stroke, transient ischemic attack or symptomatic peripheral vascular disease.
• Renal dysfunction.
• Use of insulin, glitazones, warfarin and amiodarone within 3 months before enrolment and use of potent CYP450 inhibitors, e.g., ketoconazole and macrolide antibiotics within 14 days before administration of IP.